The Patent Finder

Crossfire Oncology Holding B.V.

Also on record
Records under this name other than patents Crossfire Oncology Holding B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Crossfire Oncology Holding B.V.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US RE48,974(5,6-Dihydro)pyrimido[4,5-e]indolizines
Formerly held
In force
 · USPTO record
In forceUSPTO record
US RE50,082(5,6-dihydro)pyrimido[4,5-e]indolizines
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 12,054,784Prognostic Biomarkers for TTK Inhibitor Chemotherapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,208,696Prognostic Biomarkers for TTK Inhibitor Chemotherapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,856,258(5,6-dihydro)pyrimido[4,5-E]indolizines
Formerly held
Surrendered on reissue
Surrendered on reissue Mar 15, 2022 · USPTO record
Surrendered on reissueSurrendered on reissue Mar 15, 2022USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited